Learn more about Model-Informed Phase 3 Dose Selection for Antibody-Drug Conjugate (ADC) Sofetabart Mipitecan (Sofe-M): First Prospective Application of a Clinical Utility Index. 1016P | Oct. 23 | 3:15 - 4:00 PM | Hall 5 View program: https://t.co/jnEeGgFAl5 #GynOnc #ESMO2026 https://t.co/wnqWI8Gqu1